Skip to main navigation
  • Community
  • Product
  • Science
    • Scientific Overview
    • MC4R Pathway
    • Our Research
    • Our Focus
    • Publications
  • Clinical Trials
    • Overview
    • Emanate
    • Daybreak
    • Understanding Clinical Trials
    • Expanded Access
  • Investor Relations
    • Overview
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • News
    • Contact IR
  • About
    • Senior Management
    • Board of Directors
INVESTOR RELATIONS
  • Overview
  • Events & Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • News
  • Contact IR

News

January 23, 2023
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
January 5, 2023
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RHYTHM

Contact Us

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116

COMMUNITY
 
PRODUCT
SCIENCE
  • Scientific Overview
  • MC4R Pathway
  • Our Research
  • Our Focus
  • Publications and Presentations
  • GOLD Academy
  • Glossary
CLINICAL TRIALS
  • Overview
  • EMANATE
  • DAYBREAK
  • Understanding Clicnical Trials
  • Expanded Access
ABOUT
  • Senior Management
  • Board of Directors
INVESTORS & MEDIA
  • Overview
  • Events and Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • News
  • Contact IR
© 2023 Rhythm Pharmaceuticals, Inc. All Rights Reserved.
Rhythm, GOLD Academy, LEAD for Rare Obesity, Uncommon Obesity, Uncovering Rare Obesity, and their corresponding logos are trademarks of Rhythm Pharmaceuticals, Inc.
Terms of Use Privacy Policy